
Revolutionary computational platform analyzing individual immune cells at unprecedented scale—reducing costs by 10x while unlocking insights impossible with traditional methods.
Founded in 2019 and backed by Y Combinator, we pioneered breakthrough software for single-cell genomics—investigating immune cells one at a time to accelerate pharmaceutical development.
Think of it like this: traditional methods average traffic speed across a highway. We measure every individual vehicle, identifying the exact speeding car instantly—unlocking cellular insights impossible to detect otherwise.
Following our acquisition by Immunai in 2021, our technology now powers the world's most comprehensive digital map of the human immune system.
Pioneered million-cell analysis
Real-time computational processing
Largest immune cell database
Single-cell resolution targeting
Advanced infrastructure combining machine learning with single-cell precision
Proprietary software profiles every gene in every cell, enabling precise analysis of individual cellular activity across millions of immune cells simultaneously.
First database of 1M+ immune cells spanning healthy, cancerous, and autoimmune conditions.
Advanced models characterize immune systems across thousands of individuals at unprecedented scale.
Processed and analyzed millions of immune cells—a first in genomics
Achieved 10-fold cost reduction in single-cell sequencing operations
Built infinitely scalable computational infrastructure for analysis
Pioneered data-centric methodology for precise therapeutic targeting
Our founders emerged from the world's leading single-cell genomics laboratories, bringing decades of combined expertise in computational biology and machine learning.
PhD Bioinformatics, UCSF
Computational Biology Expert
Single Cell Genomics Pioneer
Dropprint Genomics is now part of Immunai, where we continue revolutionizing immune system understanding and accelerating life-saving drug discovery.